Verona Pharma
VRP
Performance
About Verona Pharma
Verona Pharma is a biopharmaceutical company dedicated to developing novel respiratory therapeutics to improve the lives of people with chronic lung diseases. The company focuses on conditions such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis, pursuing a broad pipeline of respiratory drug candidates. Based in the United Kingdom and operating globally, Verona Pharma emphasizes scientific research, patient insights, and investor engagement as it advances its development programs and brings innovative therapies to market.
Recent News
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
Merck to Acquire Terns Pharmaceuticals for $6.7 B, Accelerating M&A Ahead of Keytruda Patent Expiry
Report Says MSD Is in Talks to Buy Revolution Meds
UK Tech Funding Drops 11% in 2025, but Late-Stage Capital Remains Resilient
Biotech Investors Bet on a 2026 Rebound as Deal Activity Accelerates
Merck Bats Away ‘Modest Growth’ Accusations, Touts Broad Pipeline
Recent Deals
No recent deals for this company.